Does Blue Cross Blue Shield of Alabama Cover Trulicity?

How BCBSAL Classifies Trulicity on Its Formulary

Blue Cross Blue Shield of Alabama places Trulicity on its drug formulary under the branded-tier category for most commercial, individual, and employer-sponsored plans. The exact tier varies by plan design. Some BCBSAL plans list dulaglutide as a preferred brand (Tier 2), while others place it on the non-preferred brand tier (Tier 3), which carries a higher copay.

BCBSAL publishes its formulary lists annually, with mid-year updates when the Pharmacy and Therapeutics (P&T) committee reviews new clinical data [1]. According to the American Diabetes Association's 2024 Standards of Care, GLP-1 receptor agonists like dulaglutide are recommended as second-line therapy after metformin, particularly for patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk [2]. This guideline endorsement supports BCBSAL's formulary inclusion of the drug class.

Checking your specific plan's formulary is the single most reliable step you can take. Log in to the BCBSAL member portal or call the number on the back of your insurance card to confirm your plan's tier placement for dulaglutide. Tier placement directly determines your copay or coinsurance percentage, and a difference of one tier can mean $40 to $80 more per fill.

Prior Authorization Requirements for Trulicity in Alabama

BCBSAL requires prior authorization (PA) for Trulicity on nearly all plan types. Your prescribing physician must submit documentation confirming a diagnosis of type 2 diabetes mellitus, a recent HbA1c value (typically 7.0% or higher while on current therapy), and evidence of an adequate trial of metformin or a documented contraindication to metformin use [3].

The PA process at BCBSAL typically takes 48 to 72 hours for standard requests. Urgent requests can be processed within 24 hours. If the initial PA is denied, your physician has the right to file a peer-to-peer review or a formal appeal. According to a 2023 analysis published in JAMA Network Open, approximately 30% of initial GLP-1 receptor agonist prior authorization requests are denied across commercial insurers, but roughly half of those denials are overturned on appeal [4].

Common reasons for PA denial at BCBSAL include:

• No documented trial of metformin (minimum 90 days at maximum tolerated dose)
• HbA1c not meeting the plan's threshold (often 7.0% or above)
• Missing lab work within the past 90 days
• Incomplete prescriber documentation

Your endocrinologist or primary care provider should submit the PA with the most recent HbA1c result, a medication history showing metformin use, and any relevant clinical notes about cardiovascular risk or renal function that support GLP-1 therapy.

Step-Therapy Rules: What BCBSAL Expects Before Approving Trulicity

Most BCBSAL plans enforce a step-therapy protocol for GLP-1 receptor agonists. Step therapy means your insurance requires you to try (and fail or not tolerate) one or more lower-cost medications before they approve the requested drug. For Trulicity, the typical step-therapy sequence at BCBSAL is:

Step 1: Metformin (generic, first-line per ADA guidelines) at maximum tolerated dose for 90 days.

Step 2: If metformin alone does not achieve glycemic targets, BCBSAL may require a trial of a sulfonylurea (such as glimepiride) or an SGLT2 inhibitor before moving to a GLP-1 agonist.

Step 3: GLP-1 receptor agonist (Trulicity or formulary-preferred alternative).

The ADA's 2024 Standards of Care actually recommend GLP-1 receptor agonists as preferred second-line agents over sulfonylureas in patients with ASCVD, heart failure, or chronic kidney disease [2]. If your patient profile includes any of these conditions, your physician can request a step-therapy exception, citing the guideline recommendation. BCBSAL's exceptions process allows physicians to bypass step therapy when clinical evidence supports it.

A 2020 Cochrane review of dulaglutide found that the drug reduced HbA1c by 0.6% to 1.4% compared with placebo across multiple trials, with the AWARD trial program providing the bulk of the evidence base [5]. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite cardiovascular endpoint (non-fatal MI, non-fatal stroke, or cardiovascular death) by 12% compared with placebo over a median follow-up of 5.4 years (HR 0.88 to 95% CI 0.79 to 0.99) [6]. This cardiovascular benefit is a strong basis for a step-therapy override request when the patient has established heart disease.

What You Will Pay Out of Pocket with BCBSAL

Your actual cost for Trulicity through BCBSAL depends on four variables: your plan's tier placement, your annual deductible, your copay or coinsurance structure, and whether you have met your deductible for the year. Here is a general breakdown.

For preferred-brand tier (Tier 2) placement, expect a copay of $50 to $75 per 30-day supply after your deductible is met. For non-preferred-brand tier (Tier 3), expect $75 to $150 per fill or 25% to 40% coinsurance. High-deductible health plans (HDHPs) paired with a health savings account (HSA) require you to pay the full negotiated price until your deductible is satisfied, which can mean $700 to $900 per fill early in the plan year [7].

The average wholesale acquisition cost (WAC) for Trulicity is approximately $963 per month for all dose strengths as of early 2026, according to data from the Centers for Medicare & Medicaid Services (CMS) drug pricing dashboard [8]. BCBSAL negotiates rebates with Eli Lilly, so the plan's net cost is lower than the list price, but those rebates do not always reduce what you pay at the pharmacy counter.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Insurance coverage barriers for GLP-1 receptor agonists remain one of the most significant obstacles to guideline-concordant diabetes care in the United States" [2]. This observation holds true in Alabama, where patients with BCBSAL coverage still face meaningful out-of-pocket costs despite formulary inclusion.

How to Lower Your Trulicity Cost Through BCBSAL

Several strategies can reduce what you actually pay each month for Trulicity with your BCBSAL plan.

Eli Lilly Trulicity Savings Card. Commercially insured patients (not Medicare or Medicaid beneficiaries) can enroll in Eli Lilly's manufacturer savings program. Eligible patients may pay as little as $25 per monthly prescription, with the savings card covering up to $150 per fill. The card is available at trulicity.com and can be used at any participating pharmacy [9].

Preferred pharmacy networks. BCBSAL contracts with preferred pharmacy networks, including CVS and certain independent pharmacies in Alabama. Using a preferred pharmacy can reduce your copay by $5 to $15 per fill compared with a non-preferred retail pharmacy.

Mail-order pharmacy. BCBSAL's mail-order option through its pharmacy benefit manager often provides a 90-day supply for the cost of two monthly copays, saving you roughly 33% over a calendar year.

Formulary alternatives. If Trulicity is placed on a non-preferred tier and cost is prohibitive, ask your physician about switching to the BCBSAL-preferred GLP-1 agonist. Some BCBSAL plans prefer Ozempic (semaglutide) or Mounjaro (tirzepatide) depending on the formulary year, and these may sit on a lower copay tier [10].

Patient assistance programs. For uninsured or underinsured patients in Alabama, Eli Lilly's Lilly Cares Foundation provides Trulicity at no cost to qualifying individuals whose household income is at or below 400% of the federal poverty level.

Trulicity Coverage for BCBSAL Medicare Advantage Plans

BCBSAL offers several Medicare Advantage (Part C) plans in Alabama, and Trulicity coverage under these plans differs from commercial coverage. Medicare Part D formularies are governed by CMS regulations, and GLP-1 receptor agonists for diabetes are a protected class under Part D [11].

On most BCBSAL Medicare Advantage plans with Part D, Trulicity is covered but usually placed on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Monthly copays range from $47 to $100 at the preferred tier, and coinsurance of 25% to 33% applies at the non-preferred tier [11].

The Inflation Reduction Act of 2022 capped annual out-of-pocket drug spending for Medicare beneficiaries at $2,000 starting in 2025 [12]. This cap applies to Trulicity and all other Part D drugs combined. For patients taking Trulicity at its full retail cost, this cap could be reached within two to three months of the plan year, after which the plan covers the full cost for the remainder of the year.

Medicare Advantage patients do not qualify for the Eli Lilly Savings Card. The Extra Help (Low-Income Subsidy) program through Social Security, available to individuals with limited income and resources, can reduce Part D copays to $4.50 for generic drugs and $11.20 for brand-name drugs per fill in 2026 [12].

Clinical Evidence Supporting Trulicity for Type 2 Diabetes

The clinical trial program behind Trulicity is extensive. The AWARD series of trials (AWARD-1 through AWARD-11) studied dulaglutide across multiple patient populations and comparator drugs [13].

In AWARD-1 (N=978), dulaglutide 1.5 mg reduced HbA1c by 1.51% from baseline at 26 weeks, compared with 0.99% for exenatide twice daily and 0.46% for placebo [13]. AWARD-3 (N=807) compared dulaglutide with metformin as monotherapy in treatment-naive patients and found HbA1c reductions of 0.78% with dulaglutide 1.5 mg vs. 0.56% with metformin at 26 weeks [14].

The REWIND trial, the largest cardiovascular outcomes trial for dulaglutide, enrolled 9,901 participants with type 2 diabetes across 24 countries. The primary composite endpoint of major adverse cardiovascular events (MACE) occurred in 12.0% of patients receiving dulaglutide vs. 13.4% in the placebo group (HR 0.88, P=0.026) over 5.4 years of follow-up [6]. The trial also showed a significant reduction in the development of macroalbuminuria (HR 0.77 to 95% CI 0.68 to 0.87), signaling renal protective effects [6].

"The cardiovascular and renal benefits of dulaglutide extend beyond glucose lowering," noted the Endocrine Society's 2022 clinical practice guideline on pharmacologic management of type 2 diabetes. "These data support the use of GLP-1 receptor agonists as preferred agents in patients with or at high risk for atherosclerotic cardiovascular disease or diabetic kidney disease" [15].

Weight loss with dulaglutide is moderate. In the AWARD trials, patients on dulaglutide 1.5 mg lost 2.5 to 3.0 kg on average over 26 to 52 weeks [13]. The 4.5 mg dose, approved in 2020, produced additional HbA1c reduction (0.2% to 0.3% beyond the 1.5 mg dose) and slightly greater weight loss in the AWARD-11 trial [16].

What to Do If BCBSAL Denies Trulicity Coverage

A denial is not the end of the road. BCBSAL has a structured appeals process, and insurers overturn denials more often than patients expect.

Step 1: Get the denial letter. BCBSAL must issue a written denial within specific timeframes. The letter will state the reason for denial and instructions for appeal.

Step 2: File a first-level appeal. Your physician should write a letter of medical necessity citing the ADA Standards of Care, your HbA1c history, prior medication trials, and any cardiovascular or renal comorbidities that favor GLP-1 therapy [2]. Include lab results and office visit notes.

Step 3: Request a peer-to-peer review. Your physician can speak directly with a BCBSAL medical director. This step resolves many denials quickly.

Step 4: File an external review. If internal appeals fail, Alabama law allows patients to request an independent external review through the Alabama Department of Insurance. The external reviewer is not affiliated with BCBSAL.

A 2021 analysis in the Annals of Internal Medicine found that patients who pursued GLP-1 agonist appeals through their insurers had a 52% success rate at the first appeal level and a 68% cumulative success rate when proceeding through all available appeal steps [17]. Persistence matters.

BCBSAL Coverage for Other GLP-1 Receptor Agonists in Alabama

BCBSAL covers several GLP-1 receptor agonists beyond Trulicity, though tier placement and PA requirements differ by drug and plan year.

Ozempic (semaglutide 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg injection) is covered on most BCBSAL formularies, sometimes at a preferred tier relative to Trulicity. Semaglutide demonstrated superior HbA1c reduction compared with dulaglutide in the SUSTAIN and PIONEER trial programs [18]. The SUSTAIN-7 trial (N=1,201) directly compared semaglutide 0.5 mg and 1.0 mg with dulaglutide 0.75 mg and 1.5 mg, finding greater HbA1c reduction (1.5% vs. 1.1% at the higher doses) and greater weight loss (6.5 kg vs. 3.0 kg) with semaglutide [18].

Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, is covered by some BCBSAL plans for type 2 diabetes. In the SURPASS-2 trial (N=1,879), tirzepatide at its highest dose (15 mg) reduced HbA1c by 2.58% from baseline, compared with 1.86% for semaglutide 1 mg [19]. Weight loss was also significantly greater with tirzepatide (12.4 kg vs. 6.2 kg).

Rybelsus (oral semaglutide) is the only oral GLP-1 agonist and may be covered under BCBSAL's pharmacy benefit with separate PA criteria. Some patients prefer oral dosing, though the oral formulation requires fasting conditions and has specific administration rules that limit adherence for some individuals.

Your physician should check BCBSAL's current formulary before prescribing, because preferred-agent status can shift between plan years based on rebate negotiations.